David C. Mulligan

ORCID: 0000-0003-0901-2617
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Organ Transplantation Techniques and Outcomes
  • Liver Disease and Transplantation
  • Renal Transplantation Outcomes and Treatments
  • Organ Donation and Transplantation
  • Liver Disease Diagnosis and Treatment
  • Hepatitis C virus research
  • Renal and Vascular Pathologies
  • Gallbladder and Bile Duct Disorders
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Hepatitis B Virus Studies
  • Neurological Complications and Syndromes
  • Cytomegalovirus and herpesvirus research
  • Transplantation: Methods and Outcomes
  • Renal cell carcinoma treatment
  • Pancreatic and Hepatic Oncology Research
  • Clinical Nutrition and Gastroenterology
  • Diabetes Treatment and Management
  • Pancreatic function and diabetes
  • Antifungal resistance and susceptibility
  • Genetic and Kidney Cyst Diseases
  • Fungal Infections and Studies
  • Cardiac Ischemia and Reperfusion
  • Anesthesia and Sedative Agents
  • Blood groups and transfusion
  • Pediatric Hepatobiliary Diseases and Treatments

Yale University
2015-2024

University of Minnesota Medical Center
2024

Yale New Haven Health System
2024

Columbia University Irving Medical Center
2023

NewYork–Presbyterian Hospital
2023

University of Southern California
2023

New York Hospital Queens
2023

Tufts Medical Center
2023

Vanderbilt University Medical Center
2023

Lahey Hospital and Medical Center
2023

Coronavirus disease 2019 (COVID-19), the illness caused by SARS-CoV-2 virus, is rapidly spreading throughout world. Hospitals and healthcare providers are preparing for anticipated surge in critically ill patients, but few wholly equipped to manage this new disease. The goals of document provide data on what currently known about COVID-19, how it may impact hepatologists liver transplant their patients. Our aim a template development clinical recommendations policies mitigate COVID-19...

10.1002/hep.31281 article EN Hepatology 2020-04-16

The American Society of Transplant Surgeons (ASTS) champions efforts to increase organ donation. Controlled donation after cardiac death (DCD) offers the family and patient with a hopeless prognosis option donate when brain criteria will not be met. Although DCD is increasing, this endeavor still in midst development. protocols, recovery techniques acceptance vary among procurement organizations transplant centers. Growing enthusiasm for has been tempered by decreased yield transplantable...

10.1111/j.1600-6143.2009.02739.x article EN cc-by-nc-nd American Journal of Transplantation 2009-07-18

The aim of this document is to provide a concise scientific review the currently available COVID-19 vaccines and those in development, including mRNA, adenoviral vectors, recombinant protein approaches. anticipated use patients with chronic liver disease (CLD) transplant (LT) recipients reviewed practical guidance provided for health care providers involved LT about vaccine prioritization administration. Pfizer Moderna mRNA are associated 94%-95% efficacy compared placebo against COVID-19....

10.1002/hep.31751 article EN Hepatology 2021-02-14

The new allocation policy of the United Network Organ Sharing (UNOS) based on model for end-stage liver disease (MELD) gives candidates with stage T1 or T2 hepatocellular carcinoma (HCC) a priority MELD score beyond their degree hepatic decompensation. aim this study was to determine impact HCC before and after institution MELD. UNOS database reviewed all listed between July 1999 2002. were grouped by two time periods, date implementation February 27, Pre-MELD deceased donor transplantation...

10.1002/lt.20012 article EN Liver Transplantation 2004-01-01

Hepatitis C virus (HCV) recurrence after orthotopic liver transplantation (OLT) is universal. We aimed to evaluate the efficacy and safety of pegylated interferon (PEG-IFN) ribavirin (RIB) in treatment post-OLT HCV recurrence.Thirty-seven patients with recurrent OLT were screened began treatment. Nineteen have completed therapy. PEG-IFN was started at a dose 0.5 microg/kg per week titrated toward maximum 1.5 week. RIB 400 mg day 1000 day, as tolerated. Therapy continued for 1 year...

10.1097/01.tp.0000100481.14514.bb article EN Transplantation 2004-01-01

The introduction of the Mayo End-Stage Liver Disease score into Organ Procurement and Transplantation Network (OPTN) deceased donor liver allocation policy in 2002 has led to a significant increase number simultaneous liver-kidney transplants United States. Despite multiple attempts, clinical science not been able reliably predict which candidates with renal insufficiency will recover function or need concurrent kidney transplant. problem facing transplant community is that currently there...

10.1111/ajt.13631 article EN cc-by-nc-nd American Journal of Transplantation 2015-11-25

In June 2013, a change to the liver waitlist priority algorithm was implemented. Under Share 35, regional candidates with MELD ≥ 35 receive higher than local < 35. We compared distribution and mortality in first 12 months of an equivalent time period before. new listings increased slightly from 752 (9.2% listings) 820 (9.7%, p = 0.3), but proportion deceased-donor transplants (DDLTs) allocated recipients 23.1% 30.1% (p 0.001). The shares 18.9% 30.4% Sharing exports less clustered among...

10.1111/ajt.13099 article EN cc-by-nc-nd American Journal of Transplantation 2015-02-18

Objective To determine the efficacy of portal thrombendvenectomy in cases vein thrombosis at time orthotopic liver transplantation. Summary Background Data Portal (PVT) has been reported to have an incidence 2% 39% end-stage disease. Multiple techniques suggested treat this finding. Several reports suboptimal results after transplantation recipients with PVT. Methods The authors prospectively collected data on 1,546 patients who underwent initial transplant authors' institution between...

10.1097/00000658-200202000-00019 article EN Annals of Surgery 2002-02-01

Background and objectives: Hyperglycemia new-onset diabetes occurs frequently after kidney transplantation. The stress of surgery exposure to immunosuppression medications have metabolic effects can cause or worsen preexisting hyperglycemia. To our knowledge, hyperglycemia in the immediate posttransplantation period has not been studied. Design, setting, participants, &amp; measurements: We conducted a retrospective, observational study characterize prevalence assess pharmacologic management...

10.2215/cjn.05471008 article EN Clinical Journal of the American Society of Nephrology 2009-04-01

Our aim was to study the impact of subclinical inflammation on development interstitial fibrosis and tubular atrophy (IF/TA) a 1-year protocol biopsy in patients rapid steroid withdrawal (RSW). A total 256 were classified based findings at months 1 or 4. Group is 172 with no inflammation, group 2 50 (SCI), 3 19 acute rejection (SAR) 4 15 clinical (CAR). On biopsy, more (SCI) (34%, p = 0.004) (53%, 0.0002), had an IF/TA score > compared (control) (15%). not increased (CAR) (20%). The percent...

10.1111/j.1600-6143.2009.02966.x article EN cc-by-nc-nd American Journal of Transplantation 2010-02-01

This randomized, prospective, multicenter trial compared the safety and efficacy of steroid-free immunosuppression (IS) to 2 standard IS regimens in patients undergoing transplantation for hepatitis C virus (HCV) infection. The outcome measures were acute cellular rejection (ACR), severe HCV recurrence, survival. randomized (1:1:2) tacrolimus (TAC) corticosteroids (arm 1; n = 77), mycophenolate mofetil (MMF), TAC, 2; 72), or MMF, daclizumab induction with no 3; 146). In all, 295 RNA-positive...

10.1002/lt.22417 article EN Liver Transplantation 2011-08-17

Approximately two-thirds of kidney transplant recipients with no previous history diabetes experience inpatient hyperglycemia immediately after surgery; whether predicts future new onset (NODAT) is not established.A retrospective study was conducted to determine the risk conferred by on development NODAT within 1 year posttransplant. All adult nondiabetic between June 1999 and January 2008 were included. Posttransplant defined as any bedside capillary blood glucose > or = 200 mg/dl insulin...

10.2215/cjn.09481209 article EN Clinical Journal of the American Society of Nephrology 2010-06-18

The current Organ Procurement Transplantation Network policy grants Model for End-Stage Liver Disease (MELD) exception points to patients with portopulmonary hypertension (POPH), but potentially important factors, such as severity of liver disease and pulmonary hypertension, are not included in the score, may affect survival. purpose this study was identify significant predictors waitlist mortality POPH.We performed a retrospective cohort database hemodynamics consistent POPH (defined mean...

10.1097/tp.0000000000001666 article EN Transplantation 2017-02-16

Thousands of kidneys from higher-risk donors are discarded annually because the increased likelihood complications posttransplant. Given severe organ shortage, there is a critical need to improve utilization these organs. To this end, normothermic machine perfusion (NMP) has emerged as platform for ex vivo assessment and potential repair marginal In recent study 8 transplant-declined human on NMP, we discovered microvascular obstructions that impaired blood flow. However, nature physiologic...

10.1111/ajt.16148 article EN cc-by-nc-nd American Journal of Transplantation 2020-07-06
Coming Soon ...